MARKET

MESO

MESO

Mesoblast
NASDAQ
17.00
-0.43
-2.47%
After Hours: 17.00 0 0.00% 19:30 08/21 EDT
OPEN
16.98
PREV CLOSE
17.43
HIGH
17.11
LOW
16.81
VOLUME
164.75K
TURNOVER
--
52 WEEK HIGH
21.50
52 WEEK LOW
12.66
MARKET CAP
2.20B
P/E (TTM)
-23.0821
1D
5D
1M
3M
1Y
5Y
1D
Flowers Foods Posts Downbeat Q2 Results, Joins OSI Systems, Aveanna Healthcare And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
Benzinga · 1d ago
Largest borrow rate increases among liquid names
TipRanks · 3d ago
Mesoblast Completes Pivotal Phase 3 Patient Treatment for Chronic Low Back Pain
TipRanks · 4d ago
Mesoblast Targets $10 Billion Market With Regenerative Back Pain Treatment
Benzinga · 5d ago
H World Group Posts Upbeat Q2 Results, Joins Almonty Industries, Diana Shipping And Other Big Stocks Moving Higher On Monday
Benzinga · 5d ago
At a glance: stocks gapping up premarket
Seeking Alpha · 5d ago
Weekly Report: what happened at MESO last week (0810-0814)?
Weekly Report · 5d ago
Mesoblast completes patient treatment in MSB-DR004 in Phase 3 trial
TipRanks · 5d ago
More
About MESO
Mesoblast Limited is an Australia-based biotechnology company. The Company is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The Company has developing a range of late-stage product candidates, derived from its first and second generation proprietary mesenchymal lineage cell therapy technology platforms therapies for distinct indications. The Company's Ryoncil (remestemcel-L-rknd) is an allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy. Its other product candidate is Revascor (rexlemestrocel-L). Rexlemestrocel-L is second generation mesenchymal lineage precursor cell product platform and is in late-stage development for treatment of: Chronic heart failure (CHF) and Chronic low back pain (CLBP) due to degenerative disc disease. The two products have been commercialized in Japan and Europe by the Company's licensees.

Webull offers Mesoblast Ltd (ADR) stock information, including NASDAQ: MESO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MESO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MESO stock methods without spending real money on the virtual paper trading platform.